- LOGIN
- MemberShip
- 2026-04-12 05:55:22
- Company
- Whether Gardasil 9's supply price increase is reasonable
- by Jun 14, 2022 06:04am
- In order to improve the accessibility of vaccines monopolized by foreign companies, it was suggested that reasonable pricing should be monitored and institutional support measures for self-reliance should be actively reviewed. The Korea Biotechnology Industry Organization Bioeconomic Research Center said in a report titled "Controversy over domestic drug price hikes through cervical cancer vaccines" on the 13th, "Medicine prices should be reasonably priced in the drug market and should be monitored and improved if there is a competition restriction." The start is an increase in the supply of Gardasil 9, a cervical cancer vaccine for MSD. MSD raised its supply price by 25% in two years. Following the 15% increase in April last year, it decided to raise an additional 8.5 percent this year. It will be supplied at 132,636 won (excluding VAT) from July 1st. The Center for Biological Research questioned the additional increase in Gardasil 9 in MSD. "The price of drugs is set according to the logic of negotiation or free market competition with health authorities, reflecting the high failure rate, long development period, market size, and competition when developing new drugs. Excessive external intervention in the price of new drugs can hinder innovation. The center pointed out, "However, if the market dominance of certain drugs is large and the price continues to rise, the cause should be identified." In fact, Gardasil 9 accounts for 76% of the total market in the domestic cervical cancer vaccine market. There are only three types of cervical cancer vaccines: Gardasil, Gardasil 9, and Cervarix. All of them were developed by overseas pharmaceutical companies, and Gardasil 9, the latest of them, is dominating the market. Gardasil 9 prevents nine of the HPV serotypes that cause cervical cancer. The center then said, "Multinational pharmaceutical companies are emphasizing through ESG reports that they are working to expand access to medicines. MSD also said it has a role and responsibility to help improve access to medicines and vaccines around the world with the aim of sustainable development, pointing out that MSD's increase in supply of Gardasil 9 does not meet the company's goals. According to the MFDS, Gardasil 4 was also included in products that did not release generics even after patent rights expired among items with import performance of more than $10 million. The center stressed, "As the importance of health and security increases due to COVID-19, institutional support measures that can promote self-reliance in Korea should be actively reviewed if domestic development is sluggish."
- Policy
- Yoon Gov should increase bio-health investment by 15% per yr
- by Lee, Jeong-Hwan Jun 14, 2022 06:04am
- Professor Park Eun-chulProfessor Park Eun-chul said, "We need to provide intensive support for disaster medical expenses after breaking away from the Moon administration." In order for the Yoon Seok-yeol government to innovate health care, it was suggested that the bio-health government's investment ratio should be drastically increased by more than 15% every year. It is pointed out that the current bio-health government research expenses of 2.8 trillion won in 2022 should be doubled to 5.6 trillion won in 2027, five years later. He also advised that the government should have a system to strengthen disaster medical expenses by reducing the target and increasing costs by breaking away from universal medical expenses. Professor Park Eun-chul of Yonsei University's Graduate School of Health made the claim at the 2022 Health and Medical Policy Symposium held at the Seoul National University Cancer Research Institute on the 10th. Professor Park announced the theme of the Yoon Seok-yeol government's health care innovation plan. He suggested that the Yoon government significantly increase the amount of investment in the bio-health government to improve health care. It presented the Bio 2022 Health and Medical Policy Symposium as a policy task to leap forward as a global-centered country for digital health. Professor Park said that for this, the reality that the citation rate of papers in the domestic medical field is too low should be improved, and the solution is to strengthen the government's bio-health investment rate. He believes that the amount of government research funds should be more than doubled compared to this year when the government's term expires by increasing biohealth government research funds by 15% per year. Professor Park said, "The private sector pays 75% of the nation's research expenses. Large companies are investing in R&D, and all nine of the top 10 investment companies are engineering-based companies. There is no way to grow biohealth by relying on private research funds. The government should support it," he explained. Also, he said, "Biohealth government research expenses should also be increased by 15% annually," adding, "The government research expenses should be expanded from 2.8 trillion won in 2022 to 5.6 trillion won in 2027." He also suggested that the Moon Jae In government, which advocates universal health care and welfare policies, should break away from the policy as soon as possible. The Yoon Seok-yeol government should strengthen support for disaster medical expenses from the past and establish an intensive support policy for the people in need of support, not the entire people. Professor Park said that the budget for disaster medical expenses support projects should be raised to at least 500 billion won by 50 billion won a year, and later to 2 trillion won. He said, "Since the health insurance budget is 80 trillion won, it is not too much to raise 50 billion won to 500 billion won in disaster medical expenses," adding, "Public medical ratio is 61.0%, far below the OECD average of 74.1%, and if disaster medical expenses are raised, it can reach the average." "The Moon government was expensive because it targeted the entire people. The Yoon government should implement an intensive approach policy, not a universal approach, he said. "If we focus on providing disaster medical expenses to the people in need, we do not need much financial resources."
- Policy
- A petition has been filed for public consent to Enhurtu
- by Lee, Jeong-Hwan Jun 13, 2022 05:55am
- A petition for public consent has been filed to urge the health insurance coverage of HER2 (Human Epithelial Cell Growth Factor Receptor 2) low-expression breast cancer treatment Enhurtu, which is set to be approved for marketing in Korea. The petitioner, who recently filed a petition through the National Assembly, introduced to the Yoon Seok-yeol government that the cost of the Enhurtu vaccination in Korea is about 80 million won, expressing the need for domestic permission and medical insurance. More than 4,000 people have agreed to the petition, which expires on the 29th. Enhurtu is an anti-cancer drug jointly developed by Daiichi Sankyo and AstraZeneca as an antibody-drug conjugate (ADC) and approved for use in the U.S. in 2019. Now that there are no drugs to treat HER2 low-expression breast cancer, Enhurtu is considered a game changer that will change the breast cancer treatment paradigm. Experts predict that it will not be easy to apply health insurance after approval as the cost of one-cycle medication is about 20 million won, which is expensive. The petitioner, who introduced herself as a female cancer patient, said that she had been treated for seven years since the diagnosis of breast cancer in 2015, and was diagnosed by the medical staff that there was no other treatment other than Enhurtu. Because Enhurtu is not licensed in Korea, the petitioner said that Enhurtu is being imported and administered through the KOEDC, and that she is paying about 80 million won to bring it to Korea for three injections. The petitioner demanded that the medication environment be improved, such as unreasonable treatment costs, by applying the health insurance benefit. The petitioner appealed, "I took Enhurtu for the first time in Korea, so many medical staff are very interested, but medical insurance is not being applied because it is not approved in Korea." The petitioner sells out (including the house to cover the cost of the medication) but appeals because it is a burden to pay for the treatment anymore. The reality is that most people cannot get injections because it is an expensive medicine. The petitioner said, "Enhurtu is a drug used by all developed countries abroad, but only Korea cannot handle imports and insurance." Japan is also applying insurance, she said. "In order to save patients who are going to the lower world because they can't get medicine at high cost, they need to have an Enhurtu permit and medical insurance benefit."
- InterView
- Otrivin package made user-friendly for pharmacist & patient
- by Eo, Yun-Ho Jun 13, 2022 05:55am
- Yewon Moon, Brand Manager, GSK Consumer Healthcare One strong perception of allergic rhinitis is that its symptoms worsen during the change of seasons and then decrease in summer. However, the large temperature difference between indoors and outdoors in summer due to excessive operation of air conditioners can dry out the mucous membranes and further weaken the immune system. Topical decongestant nasal sprays are one of the most popular products sought by customers due to rapid symptom relief. The spray constricts the blood vessels in the nasal mucosa to relieve symptoms of nasal obstruction to offer faster symptom relief than oral formulations and is effective in those who experience severe nasal congestion. However, people are reluctant to use the spray formulation due to the risk of side effects that can occur if users do not follow the correct method of its use. One well known side effect is rhinitis medicamentosa, or rebound congestion, which worsens the dryness in the nose and rhinitis. For its proper use, topical decongestant nasal sprays should not be used more than 3 times a day (up to 2 times a day for oxymetazoline products) and should not be used for more than a week at a time in adult patients. Also, a recovery period is required after its use for one week in a row. GSK Consumer Healthcare Korea announced a package renewal plan for its leading nasal decongestant ‘Otrivin.’ Dailpharm met with Yewon Moon, Brand Manager at GSK Consumer Healthcare who has been working to deliver the correct method of use of nasal decongestants. -Otrivin’s logo and the package have been renewed after 3 years. Its strong visual consistency seems to be one of its leading features. Could you introduce the changes? We used intuitive icons and vivid colors in the design. Consumers can easily locate Otrivin thanks to the ‘BlueRing’ design, and the package is structured to provide easier and quicker understanding of the product's efficacy and effect. Consumers would want to quickly find and purchase the product they need to relieve their nasal congestion. Therefore, we focused foremost on how to improve the convenience of purchase for our consumers in our package renewal. -What design element did you focus most on?? Of course, we considered each and every element in the process of renewing the package with a particular focus on the front design. The BlueRing design in the front allows consumers and pharmacists to quickly locate the Otrivin brand. The key focus of the renewal had been on clearly conveying the effects of each product. -What did consumers respond best to in the consumer testing process? Global test results showed that the consumers’ purchase intent increased because the new package provided a clearer understanding of each product’s effect. Brand search rate has also increased, and the modern design of the package contributed to increasing the positive image of the product. -I believe the new package will be useful not only for the consumers who purchase the product but on the pharmacy’s part as well. How will pharmacies and pharmacists benefit from the renewed package? As the design change allows for clearer delivery of the effect of each product, I believe this would help pharmacists conduct easier medication counseling on which Otrivin should be used according to each patient’s age and symptom. -When will it be released in Korea? Where can we find the renewed version? The period of each product’s release may differ somewhat, but we are preparing so that the renewed Otrivin 0.05% Pediatric, Otrivin Menthol 0.1%, Otrivin Baby Natural, and our newest product ‘Otrivin S’ can be found at pharmacies in Korea within the second quarter of this year. For your reference, the package design renewal is being made as a global project, but the period of renewal in each country will be conducted sequentially, subject to each country’s situation. -Do you have any other plans on providing support for pharmacies other than changing the package, with posters, etc.? We plan to improve access to Otrivin within pharmacies with the new package design during the change of seasons when an increasing number of consumers seek nasal decongestants. With the colors more easily discernable than in the past, the new Otrivin package will aid consumers in selecting the product they need and stand out from other products on display at pharmacies. Even when it is behind counters, pharmacists will be able to save the time that they had previously wasted looking for Otrivin due to the easily identifiable package. Also, we are preparing communication with pharmacies to facilitate smoother medication counseling on Otrivin for consumers at pharmacies.
- Product
- Prescription of oral COVID-19 drugs drop to 1,800 last week
- by Kang, Shin-Kook Jun 13, 2022 05:54am
- Prescriptions of the oral COVID-19 treatments Paxlovid and Lagevrio have been rapidly decreasing in line with the decrease of confirmed COVID-19 cases in Korea. On the 10th, the Korea Disease Control and Prevention Agency announced that it had prescribed Paxlovid and Lagevrio to 1,800 patients during the past week. From 6:30 p.m. on May 3rd to 6:30 p.m. on May 9th, 1,549 courses of Paxlovid had been prescribed to patients receiving treatment from home, at residential treatment centers, and at infectious disease hospitals. In the case of Lagevrio, another oral COVID-19 treatment, 258 courses were prescribed in the same period. Compared to two months ago when prescriptions of Paxlovid amounted to 29,746 in the week of April 11th, the 1,549 prescriptions made last week is a 1/19th decrease in just two months. As a result, 469,923 courses of Paxlovid and 78,402 courses of Lagevrio remain in stock, amounting to a total of 548,325 courses of oral COVID-19 treatments available for use in Korea.
- Policy
- Novartis' new adult leukemia drug Scemblix has been approved
- by Lee, Hye-Kyung Jun 13, 2022 05:54am
- Scemblix, a treatment for Ph+ CML adult patients, has obtained domestic permission. The MFDS approved Scemblix 20mg and Scemblix 40mg applied by Novartis on the 9th. Scemblix is used in the treatment of chronic Ph+ CML adult patients who have previously been treated with two or more TKI. The efficacy was based on MMR and Cytogenetic Response. Scemblix is taken on an empty stomach and the recommended daily dose is 80 mg. Changes in dosage are determined at the discretion of the physician according to the need for patient management. Scemblix administration should continue until clinical benefits are observed or unacceptable toxicity appears. Scemblix previously treated Ph+ CML patients and T315I mutant-expressed Ph+ CML-CP patients based on MMR at the 24th week of the U.S. Food and Drug Administration (FDA) on October 29 last year. FDA approval was based on the results from the ASC4FIRST phase 3 clinical trial and NCT02081378 phase 1 clinical trial. In this study, Scemblix was found to have improved the ratio of major molecular reactions (MRR) at 24 weeks more than twice compared to the control group, Pfizer's Bosulif.
- Policy
- The risk group for COVID-19 depression was 18.5%, down
- by Lee, Jeong-Hwan Jun 13, 2022 05:54am
- The COVID-19 depression risk group surveyed in the first quarter of this year was 18.5%, down from 22.8% in March last year. It is still high compared to 3.2% in 2019, before COVID-19, and the government plans to push for COVID-19 psychological support for daily recovery. On the 3rd, the MOHW made the announcement at a regular briefing on COVID-19. According to the COVID-19 National Mental Health Survey of 2,063 adults nationwide, the depression risk group is on the decline to 18.5%. Specifically, the risk group for depression in March 2020 is decreasing to 18.5% this year, compared to 17.5% in March 2020, 22.8% in March last year, and 18.9% in December last year. However, it is still higher than 3.2% in 2019, before COVID-19. By gender, 20.3% of women were higher than 16.7% of men. In addition, 22.7% of those whose income decreased were at higher risk of depression than 16.7% of those whose income increased or did not change. The suicide rate surveyed in March this year was 11.5%, which was also on the decline, but it was still higher than 4.6% in 2019, before COVID-19. Like the depression risk group, by age, those in their 30s (15.2%), those in their 40s (13.3%), and those in their 20s (11.9%) were high, and those in their 20s (15.2%) were high. By gender, men (12.2%) were higher than women (10.9%). Based on the results of a survey on COVID-19 depression, the MOHW prepares and promotes psychological support measures for daily recovery. According to the transition of the general medical system during daily recovery, psychological support for confirmed patients is converted from existing national and regional trauma centers to local mental health welfare centers to provide comprehensive mental health services in the local community. It also provides customized services for children, adolescents, young people, women, workers, and small business owners who are vulnerable to mental health. The MOHW said, "We will continue to promote psychological support so that government ministries and local governments can restore the people's daily lives in good health and actively support anyone who needs help."
- Company
- Hanall Biopharma to expand HL161 development in earnest
- by Chon, Seung-Hyun Jun 10, 2022 05:44am
- Hanall Biopharma announced on the 9th that its U.S. partner Imunovant will expand the development of HL161 (code name IMVT-1401), which is being developed as a SC autoimmune treatment. Phase 3 clinical trials for severe work history will begin this month and the results of the top line in 2024 will be confirmed. According to Immunovant, there are estimated to be about 66,000 patients with severe work history in the United States. Clinical plans for TED, which were suspended last year, have also been unveiled. Immunovant obtained consent from the U.S. Food and Drug Administration (FDA) for phase 3 clinical trials of HL161. Phase 3 clinical trials are expected to begin in the second half of this year and confirm the results in 2025. Imunovant also unveiled a plan to further expand the indication of HL161 to provide wider treatment options for patients suffering from intractable diseases. By August, three indications, including WAIHA, will be added and phase 3 clinical trials will be launched for one of them. HL161 is the U.S. and European development name of the new antibody drug HL161, which Hanall Biopharma exported to Roivant Sciences in December 2017. It exhibits a mechanism of action to remove pathogenic autoantibodies in the body by inhibiting the 'FcRn' receptor known as the cause of autoimmune diseases. Roivant Sciences has signed a total of $52.5 million contract with Hanall Biopharma on condition that it secures exclusive rights to develop, produce, item licenses, and sell autoimmune disease HL161 in the U.K., Switzerland, the Middle East and North Africa, including the U.S. At the time of the contract, it paid $30 million in deposit (upfront fee), which was not obligated to return, and additional $20 million in research funds and $452.5 million in step-by-step milestones (technical fees). Imunovant decided to voluntarily suspend clinical trials early last year on the grounds that a rise in total cholesterol and LDL-C levels was observed in the HL161 administration group among patients participating in clinical trials 2b. Chung Seung-won, CEO of Hanall Biopharma, said, "HL161 is expected to reduce the burden of medical expenses because it is convenient for patients to take drugs on their own in the form of subcutaneous injections." "We will continue to expand the indication of HL161 to contribute to the lives of more patients," he said.
- Company
- Exports of CKD·Dong-A ST's antianemic biosimilars increase
- by Chon, Seung-Hyun Jun 10, 2022 05:43am
- The biosimilar products developed by Chong Kun Dang and Dong-A ST are starting to make their way into the overseas market, with its Nesp biosimilars starting to generate sales in earnest abroad. Although the companies’ products did not show explosive growth upon entry, the products are increasing their presence in the market. According to the Financial Supervisory Service, Chong Kun Dang’s export sales recorded ₩19.4 billion in Q1 this year, a 57.7% increase compared to sales made in the same period of the previous year. Compared to the ₩10.6 billion it had made in Q1 2020, the scale of exports increase 82.3% in two years. In the case of Chong Kun Dang, the company’s sales had been solely dependent on domestic demand. Its exports in Q1 2019 were a mere ₩6.3 billion. Chong Kun Dang’s ‘Nesbell’ is being highlighted as the driver of CKD’s recent growth in exports. New drug products being developed by Hanmi Pharmaceutical have received a total of 20 orphan drug designations from regulatory authorities in Korea and abroad. Hanmi Pharmaceutical announced on the 9th that the European Medicines Agency granted an orphan drug designation for its new triple action biologic drug LAPS Triple Agonist (HM15211) for the treatment of Idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a rare condition caused by an unknown pulmonary inflammatory process and fibroblast hyperproliferation. Patients with IPF experience a rapid decline in lung function from tissue fibrosis and even death. Although it occurs in less than 100 cases per 10,000, its treatment had been rendered difficult due to the lack of efficacy in its approved treatments. LAPS Triple Agonist is a triple-action biologic drug that activates GLP-1, Glucagon, and GIP. It simultaneously targets▲ Glucagon, which inhibits fibrosis ▲ GLP-1, which facilitates insulin secretion and helps suppress appetite, and ▲ GIP, which facilitates insulin secretion and anti-inflammatory effect. Hanmi Pharmaceutical had confirmed its drug’s antiinflammatory and antifibrotic in animal models with idiopathic pulmonary fibrosis. With the designation Hanmi Pharmaceutical received a total of 20 orphan drug designations for its 10 indications in 6 pipelines (9 FDA designations, 8 EMA designations, and 3 Korea MFDS designations). LAPS Triple Agonist received a total of 6 orphan drug designations from both the FDA and EMA for the treatment of ▲primary biliary cholangitis, ▲primary sclerosing cholangitis, and ▲IPF. The FDA and EMA grant orphan drug designations to facilitate smooth development and approval of drugs that treat rare, incurable, or life-threatening diseases. In Europe, drugs that receive the designation pay reduced fees for marketing-authorization applications and may benefit from ten years of market exclusivity once they receive marketing authorization in the European Union (EU) An official from Hanmi Pharmaceutical said, “All the indications that the drug received orphan drug designation on induces fibrosis in specific tissues and has high unmet needs. LAPS Triple Agonist’s designation has meaning in that the drug's innovativeness is receiving attention from regulatory agencies in advanced countries. Nesbell is a biosimilar of the second generation anemia treatment ‘Nesp (darbepoetin-α).’ It is prescribed to treat ▲anemia in chronic kidney disease patients and ▲anemia in patients with solid cancer who receive chemotherapy. Chong Kun Dang received marketing approval from Japan's Ministry of Health, Labor, and Welfare in September 2019. The Japanese subsidiary of U.S. global pharmaceutical company Mylan N.V. is in charge of sales in Japan. Analysts believe that the continued growth of Nesbell’s sales in Japan had driven the continued growth of Chong Kun Dang’s export in Japan. Nesbell holds great significance for the company as it is the first biosimilar that it succeeded in developing. Chong Kun Dang entered the biosimilar market after securing its own platform technology in 2008. After initiating a Phase I trial on Nesbell in 2012, Chong Kun Dang succeeded in becoming the first company to commercialize a biosimilar of Nesp by receiving marketing approval for Nesbell from the Ministry of Food and Drug Safety at the end of 2018. Nesbell is also set to enter the Middle East soon. Chong Kun Dang signed an export agreement for Nesbell with an Oman company Menagene Pharmaceutical Industries in July last year. Under the agreement, Menagene Pharmaceutical Industries will be acquiring the marketing authorization and own the exclusive rights to sell Nesbell in 6 countries in the Middle East, including Oman, Saudi Arabia, Chong Kun Dang starts supplying its finished Nesbell product to United Arab Emirates, Kuwait, Qatar, and Bahrain. The drug is also increasing its presence in the Korean market. According to the market research institution IQVIA, Nesbell’s sales last year amounted to ₩4.8 billion, which was a 150.9% YoY increase. Its sales had only been ₩0.3 billion and ₩1.9 billion in the first year of its release and 2020, respectively. Its sales has risen significantly last year to increase its market share in the same ingredient market to 18.5%. Dong-A ST’s Nesp biosimilar ‘Darbepoetin-α’ is also slowly increasing its influence in the market. After conducting a Phase 1 clinical trial on’ Darbepoetin-α,’ Dong-A ST signed a licensing-out agreement on the development and sale of its drug to Sanwa Kagaku Kenkyusho (SKK). Based on a Phase III trial conducted in Japan to compare the efficacy and safety of ‘Darbepoetin-α’ to the original ‘Nesp,’ SKK received marketing approval from Japan's Ministry of Health, Labor and Welfare for the drug in September 2019 and launched the drug for sale in November of the same year. Dong-A ST exports the finished products which were produced by DM Bio, a biosimilar company under Dong-A Socio Group, to SKK, after which SKK takes charge of its local sales. Darbepoetin-α’s exports increased 13.8% YoY to record ₩3.3 billion in Q1 this year. This is a decrease from the ₩6.1 billion made in Q4 last year, but still has been making ₩3 billion in sales every quarter. Darbepoetin-α had first made ₩1 billion in the first year of its release, which increased to ₩8.8 in 2020. Its sales then exceeded ₩10 billion in annual sales for the first time last year, recording ₩12.5 billion. Darbepoetin-α’s cumulative sales totals at ₩25.6 billion.
- Company
- Sanofi & 4 other companies will participate in NIP
- by Lee, Tak-Sun Jun 10, 2022 05:42am
- Unlike the previous year, Sanofi Pasteur is expected to participate as a new business operator and Ilyang Pharmaceutical is expected to be excluded. As a result of the bidding conducted through the Nara Market of the Public Procurement Service on the 9th, Sanofi Pasteur was selected as the first choice by writing the lowest price of 14,433. The desired quantity is 2.2 million doses.The second ranking is Korea Vaccine, which participated in 16,670 won, and the desired quantity is 1.7 million doses. The third place is Boryung Bio Pharma, which spent 16,887 won, and the desired quantity is 1.8 million degrees. The fourth ranking was GC Pharma, which offered 10,700 won, and the desired quantity was 6 million doses. Ilyang Pharmaceutical has bid 10,700 won, the same as the GC Pharma, but the desired quantity is 1.9 million doses, which is less than the GC Pharma, so it is expected to be pushed back from the priority. In this bid, the bidder until the purchase quantity reaches the lowest price among the bidders at a unit price below the scheduled price shall be the successful bidder. All five companies that participated in the bidding had lower bidding prices than the scheduled price of 10,807 won. The KCDA suggested a total of 10,665,090 doses. Looking at the desired quantity in the order of the lowest price, the three companies will easily be included in the total purchase volume, with 2.2 million doses of Sanofi, 1.7 million doses of Korean vaccine, and 1.8 million doses of Boryeong Biopharma. The combined total number of these companies is 5.7 million. The remaining quantity is about 4.96 million doses, which is expected to be taken by the GC Pharma which wants 6 million doses. Ilyang Pharmaceutical has written the same price as GC Pharma, but if there are more than two bidders of the same price, it will be pushed out of the bidding range because it prioritizes bidders with high bidding volume. However, the final successful bidder is determined according to the qualification for participation in the bid and the results of the qualification examination. However, as these companies have a lot of experience in participating in the free flu vaccination project, it is expected that the successful bidder will be determined according to the results of the ticket gate unless there is an accident. Performance of Sanofi is 22.3 billion won, Korea Vaccine, 18.1 billion won, Boryung Biopharma, 19.2 billion won, and GC Pharma, 53 billion won. Compared to last year, the supply volume is the result of an increase of about 1 million doses of green cross, 400,000 doses of Korean vaccine, and 200,000 doses of Boryung Biopharma. Sanofi, which was absent last year, will be the only foreign pharmaceutical company to participate and be selected as the top priority, and will supply the second largest quantity after GC Pharma. GSK, which supplies Fluarix Tetra PFS, a quadrivalent vaccine aid, will not participate in the NIP business again this time.
